

ARTICLE OPEN



Maintenance of magnesium homeostasis by NUF2 promotes protein synthesis and anaplastic thyroid cancer progression

Lisha Bao^{1,5}, Yingying Gong^{1,5}, Yulu Che^{2,5}, Ying Li², Tong Xu², Jinming Chen², Shanshan Wang², Zhuo Tan^{1,3,4}, Ping Huang^{2,3,4}, Zongfu Pan^{2,3,4} and Minghua Ge^{1,3,4}

© The Author(s) 2024, corrected publication 2024

Thyroid cancer is the most frequently observed endocrine-related malignancy among which anaplastic thyroid cancer (ATC) is the most fatal subtype. The synthesis of protein is active to satisfy the rapid growth of ATC tumor, but the mechanisms regulating protein synthesis are still unknown. Our research revealed that kinetochore protein NUF2 played an essential role in protein synthesis and drove the progression of ATC. The prognosis of patients with thyroid carcinoma was positively correlated with high NUF2 expression. Depletion of NUF2 in ATC cells notably inhibited the proliferation and induced apoptosis, while overexpression of NUF2 facilitated ATC cell viability and colony formation. Deletion of NUF2 significantly suppressed the growth and metastasis of ATC in vivo. Notably, knockdown of NUF2 epigenetically inhibited the expression of magnesium transporters through reducing the abundance of H3K4me3 at promoters, thereby reduced intracellular Mg²⁺ concentration. Furthermore, we found the deletion of NUF2 or magnesium transporters significantly inhibited the protein synthesis mediated by the PI3K/Akt/mTOR pathway. In conclusion, NUF2 functions as an emerging regulator for protein synthesis by maintaining the homeostasis of intracellular Mg²⁺, which finally drives ATC progression.

Cell Death and Disease (2024)15:656; <https://doi.org/10.1038/s41419-024-07041-6>

INTRODUCTION

Thyroid cancer (TC) is the most common endocrine-related carcinoma, accounting for over 90% of all endocrine malignancies [1]. Anaplastic thyroid cancer (ATC) is the lethal subset of TC with a median survival of only six months and responsible for 40–50% of total TC-related deaths [2]. Different from other common TC subtypes, ATC grows rapidly, leading to symptoms of neck compression such as dyspnea, dysphonia, and dysphagia [3, 4]. Therefore, it is important to identify the mechanism of ATC progression.

Dysregulated protein synthesis has been shown to be one of the main characteristics of cancer [5]. To satisfy the internal oncogenic demands and external factors in the tumor micro-environment, cancer cells synthesized proteins rapidly and selectively [6]. Intracellular magnesium plays a positive role in the regulation of protein synthesis and cell proliferation [7–9]. The homeostasis of intracellular magnesium is regulated by magnesium transporters such as MAGT1, NIPA1, and NIPAL1 [10–13]. Magnesium ion is indispensable to tumor proliferation and development [14], and hypomagnesemia inhibits tumor growth and angiogenesis [15]. Studies have shown that the expression of MAGT1 impacted the progression of cancer [16, 17], and NIPA1 [18, 19] and NIPAL1 [20, 21] were related with poor prognosis. Cancer cells preferentially translate

oncogenic proteins, thereby contributing to tumor growth, metastasis, and therapy resistance [22]. In ATC, the protein synthesis is also active supported by increased eukaryotic initiation factor 4E (eIF4E) and ribosome biogenesis pathway [23–26], thereby enhancing its aggressiveness and chemoresistance. Nonetheless, the exact mechanism underlying protein synthesis in ATC remains elusive.

As a constituent part of the NDC80 kinetochore complex, NUF2 is known to have a role in mitotic chromosomal alignment and the establishment of stable kinetochore-microtubule attachments [27]. The depletion of NUF2 blocked prometaphase with an active spindle checkpoint significantly [28]. NUF2 was upregulated in various kinds of cancers and regarded as a promising antitumor therapeutic target and prognostic factor [29]. Of note, several studies point out that NUF2 functions as an oncogenic regulator beyond kinetochore protein. For example, NUF2 was identified as a new cancer stem cell indicator [30]. In addition, NUF2 has been found to drive cancer development through inhibiting autophagic degradation of oncogene TFR1 [31] or affecting the transcription of HMGA2 [32]. Studies have shown that NUF2 not only affects the G2/M phase by interfering with centromere function [33], but also acts on the S phase, where protein synthesis occurs [31, 34]. However, there are few studies about the exact function of NUF2 in ATC.

¹Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. ²Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China. ³Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China. ⁴Zhejiang Provincial Clinical Research Center for malignant tumor, Hangzhou, China. ⁵These authors contributed equally: Lisha Bao, Yingying Gong, Yulu Che. ✉email: huangping@hmc.edu.cn; panzongfu@163.com; geminghua@hmc.edu.cn
Edited by Stephen Tait

Received: 29 January 2024 Revised: 15 August 2024 Accepted: 29 August 2024

Published online: 06 September 2024

In this study, the role and mechanisms of NUF2 in ATC were investigated. We found that NUF2 epigenetically regulates the transcription of magnesium transporters, thereby promoting protein synthesis through PI3K/Akt/mTOR pathway in ATC. Our findings extend the notion that NUF2 acts as an emerging regulator of magnesium homeostasis during protein synthesis and ATC progression.

METHODS

Bioinformatic analyses

The survival curve in thyroid cancer was applied by the Kaplan-Meier plotter (<http://kmpplot.com/analysis>). The expression level of NUF2 in TC based on nodal metastasis status was applied by UALCAN (<https://ualcan.path.uab.edu/index.html>). Four microarray datasets (GSE29265, GSE33630 [35], GSE65144 [36], and GSE76039 [37]) were integrated to generate a large thyroid-cancer cohort including 78 normal thyroid tissue, 69 PTCs, 17 poorly differentiated thyroid cancers (PDTCs), and 52 ATC samples as reported previously [38]. The expression of NUF2 in different groups was displayed by ggplot2 package. mTOR signaling pathway genes were obtained from Enrichr database (<https://maayanlab.cloud/Enrichr>) to calculate the enrichment scores by GSEA package. The relationship between the mTOR signaling score and NUF2 expression in ATC was analyzed using Spearman correlation analysis. $P < 0.05$ was considered to indicate statistical significance.

Clinical samples

The tissue microarray including 11 normal thyroid tissues, 8 PTC, and 5 ATC were provided by Zhejiang Provincial People's Hospital. This study was undertaken following the Declaration of Helsinki and approved by the Ethics Committee of Zhejiang Provincial People's Hospital.

Cell culture

The thyroid follicular epithelial cell line Nthy-ori 3-1 (ECACC, Cat# 90011609), PTC cell line BCPAP (DSMZ Cat# ACC-273), ATC cell lines 8505C (DSMZ, Cat# ACC-219) and KHM-5M (National Collection of Authenticated Cell Cultures, Cat# SCSP-549), were cultivated in RPMI-1640 supplied with 10% fetal bovine serum (Gibco, Waltham, MA, USA) in 37 °C atmosphere containing 5% CO₂.

Small interfering RNA (siRNA) transfection and lentiviral infections

siRNAs targeting human NUF2 (the sense sequence was GCCGTGAAACG-TATATGGAAT and the anti-sense sequence was AUUCCAUUACGUUUCACGGC), MAGT1 (the sense sequence was GCTCATCGTTTGCGACGTT and the anti-sense sequence was AACGUCGCAAACGAGUAGC), NIPA1 (the sense sequence was GCCCAAGACATCTTGCATA and the anti-sense sequence was UAUGCAAGAUGUCUUGGGC), and NIPAL1 (the sense sequence was GCTCCAGCTTCATACTGAA and the anti-sense sequence was UUCAGAUGAAGCUGGAGC) were purchased from Ribobio (Guangzhou, China). Cells were seeded to a density of 30–40%, and siRNA and jetPRIME (Ployplus, France) were added to the culture medium. Lentiviruses for knockdown and overexpression of NUF2 and their controls were synthesized by ABM (Richmond, Canada). 4 µg/mL puromycin was used to construct stable cell lines of 8505C and BCPAP.

Western blotting and nucleocytoplasmic separation

Total cellular protein was extracted using RIPA lysis buffer (Applygen, China, C1053-100) and quantified by Coomassie brilliant blue G-250 (Solarbio life science, China, Cat# PC0015). The extraction of nuclear and cytoplasmic proteins was performed using the nuclear-cytosol extraction kit (Applygen Technologies, China, Cat# P1200) according to the instructions. Separated by 10% SDS-PAGE gel electrophoresis, the denatured protein samples were then transferred onto the PVDF membrane (Millipore, IPFL00010). After being blocked with 5% BSA at room temperature (RT) for 1 h, the PVDF membrane was incubated with the primary antibody overnight at 4 °C and washed with Tris-buffered saline Tween (TBST) for 3 times. And then, corresponding HRP-conjugated secondary antibody was added and incubated at RT for 1 h. Images were detected by enhanced chemiluminescence. The antibodies used were listed in Table 1.

Table 1. The antibody used for Western blot.

Antibody	Company	Concentration
NUF2	ABclonal, Cat# A17553	1:1000
MAGT1	Proteintech Cat#17430-1-AP	1:1000
NIPA1	Santa, Cat#sc-398041	1:500
NIPAL1	Lsbio, Cat#LS-C164878	1:500
p-mTOR	Cell Signaling Technology, Cat#5536	1:1000
mTOR	Cell Signaling Technology, Cat#2983	1:1000
p-AKT	Cell Signaling Technology, Cat#4060	1:1000
AKT	Cell Signaling Technology, Cat#4691	1:1000
p-PI3K	Affinity, Cat#AF6241	1:1000
PI3K	ABclonal, Cat#A4992	1:1000
H3K4me3	ABclonal, Cat#A22146	1:1000
H3K27ac	ABclonal, Cat#A2771	1:1000
GAPDH	ABclonal, Cat# AC002	1:5000

Table 2. The primers used for RT-qPCR.

Genes		primer sequence
GAPDH	Forward	5'-GCACCGTCAAGGCTGAGAAC-3'
	Reverse	5'-TGGTGAAGACGCCAGTGGGA-3'
NUF2	Forward	5'-TGAAAGATACGGTCCAGAAGC-3'
	Reverse	5'-ACTGCACTTCCAAGTACATG-3'
MAGT1	Forward	5'-AAGCCCCACCGAGAAATTAC-3'
	Reverse	5'-TGAATGCACTGGAGTATCGC-3'
NIPA1	Forward	5'-CTACAGAAGAAGGGCATCGTG-3'
	Reverse	5'-CCGTGTAAGCCAGGAAGTTTC-3'
NIPAL1	Forward	5'-CAGGAGAGGCTGCAAATTTTG-3'
	Reverse	5'-CAGCCTATTTCCCATGAATGTTTC-3'

RNA preparation and real-time quantitative reverse transcription (RT-qPCR)

Extracted with the RNA-Quick Purification Kit (Esunbio, China), the total RNA was reversely transcribed into cDNA using the Fast All-in-One RT Kit (Esunbio, China) for qPCR. PCR amplification was performed using Super SYBR Green qPCR Master Mix (Esunbio, China). The expression levels of different genes were calculated using the $2^{-\Delta\Delta CT}$ method and standardized to GAPDH. The primers used for RT-qPCR were listed in Table 2.

Tissue specimens and immunohistochemistry (IHC)

Paraffin-embedded tissues were sliced and deparaffinized, and then dewaxed and hydrated with xylene and alcohol. The tissue sections were subjected to 1 mM EDTA (pH 8.0) for antigen repair. The endogenous peroxidase was blocked by 0.3% hydrogen peroxide followed by treated with 3% goat serum for 30 min at RT. Primary antibodies were incubated on the slices overnight at 4 °C, followed by a 50-min RT secondary antibody incubation. Primary antibodies were listed following NUF2 (Novus, America) and p-mTOR (Proteintech, America). The immunoreaction intensity was scored as follows: negative = 0, weak = 1, moderate = 2, strong = 3. The percentage of stained cells was scored as follows: negative = 0, 0–25% = 1, 26–50% = 2, 51–75% = 3, 76–100% = 4.

Cell viability and colony formation assay

For the cell growth assay, 3000 cells were seeded in 96-well plates. After 48 h of culture, the cells were incubated with 10 µL CCK-8 solution (FDBio, FD3788) and 90 µL PBS at 37 °C for 1 h, and then the absorbance was detected at 450 nm using the microplate reader. For the colony formation

assay, KHM-5M (1000 cells) and 8505C (2000 cells) were seeded into 6-well plates and fixed after 10–14 days, and then these cells were stained with 0.2% crystal violet.

After being washed with PBS twice, the ATC cells transfected with siRNA for 48 h were incubated with Calcein AM/PI detection solution at 37 °C for 30 min protected from light according to the protocol of Cytotoxicity Assay Kit (Beyotime, China). The staining effect was observed and imaged with a fluorescence microscope.

Flow cytometry

Annexin-V/FITC Apoptosis Kit (Multi Sciences Biotech, China) was used to assess cell apoptosis at 48 h after siRNA transfection. We resuspended the cells in 500 μ L of 1 \times binding buffer. And then, cells which were incubated with 5 μ L FITC Annexin V and 10 μ L PI for 15 min at RT in the dark were detected by flow cytometry (FCM) for cell apoptosis analysis.

For cell cycle analysis, the Cell Cycle Staining Kit (Multi Sciences Biotech) was used following the manufacturer's procedure. The collected cells were incubated for 30 min at RT in the dark with 1 mL DNA Staining Solution and 10 μ L Permeabilization Solution. Then, the cell cycle was analyzed by FCM.

Cell precipitate was collected and incubated with NUF2 antibody (1:200) overnight at 4 °C on a shaker. After washing the cells with PBS, fluorescent secondary antibody (1:200) was added and incubated for 2 h at RT in the dark. And then, the cell cycle was detected by the Cell Cycle Staining Kit and FCM. Flowjo V10 software was used to analyze the expression of NUF2 in different cell cycles.

CFSE cell proliferation assay

The cells were resuspended in serum-free medium, and 1 μ L CFSE dye was added per 10 million cells to incubate the cells in a cell incubator. After 20 min, the staining was terminated by adding complete medium. After centrifugation, the cells were resuspended in the cell medium and counted, seeded in culture plates according to experimental requirements, and collected 48 h after siRNA transfection and detected by flow cytometry.

RNA-seq analysis

Total RNA of NUF2-WT and NUF2-KD 8505C cells was isolated and purified. After quality control, Poly (A) RNA was purified and fragmented into small pieces which be synthesized into cDNA using Invitrogen SuperScript™ II Reverse Transcriptase (Thermo Fisher). Then, the ligated products were amplified with PCR. Finally, the 2 \times 150 bp paired-end sequencing was carried out on illumina Novaseq™ 6000 (LC-Bio Technology, China).

Sequence quality control was performed using fastp software. Reads were mapped to the reference genome of Homo sapiens GRCh38 using HISAT2 and then assembled and calculated using StringTie (<https://ccb.jhu.edu/software/stringtie>). The differentially expressed genes (DEGs) were screened with fold change >2 or <0.5 and with parametric F-test comparing nested linear models ($P < 0.05$). DAVID software (<https://david.ncifcrf.gov/>) was used for Gene ontology (GO) enrichment analysis on DEGs. RNA-Seq data has been submitted to the GEO repository under accession number GSE272374.

Dual-luciferase assay

293T cells were preseeded in 12-well plated with a density of 50%, and co-transfected with 500 ng luciferase reporter plasmid, and renilla luciferase reporter vector pGL-3 per well using Lipofectamine™8000 for 48 h. The experimental group was transfected with NUF2 overexpression plasmid and the control group was transfected with empty vector pcDNA3.1 for 48 h. Cells were collected and the luciferase activity was analyzed by dual-luciferase reporter gene assay kit (Beyotime, China). The firefly luciferase activity was normalized to the renilla luciferase activity that reflects expression efficiency.

Coimmunoprecipitation (CoIP)

The protein lysates were immunoprecipitated with specific antibodies targeting against NUF2 (1:50, Novus, nbp2-99081) or IgG negative control (1:50, Beyotime, A7016) at 4 °C overnight in the rotator and then incubated with 50 μ L Protein A/G Magnetic Beads pre-washed with RIPA buffer for 2 h at 4 °C in the rotator. Subsequently, the beads were collected and washed 3 times with RIPA buffer, and the immunoprecipitation compounds were separated from the beads for following western blot analysis.

Table 3. The primers used for ChIP-qPCR.

Genes		primer sequence
MAGT1	Forward	5'-TGCTCAGTCGTGTCCAACCT-3'
	Reverse	5'-TGGACTGGATAGCACCTGA-3'
NIPA1	Forward	5'-CTGTCCCCGAGCCTAAG-3'
	Reverse	5'-AGCTGCAGTCCCCATTCC-3'
NIPAL1	Forward	5'-AGCTTCCATCCTGCAA-3'
	Reverse	5'-CTCTTCCCCTACCACGC-3'

Chromatin immunoprecipitation (ChIP)

The ChIP Assay Kit (Beyotime, China, P2078) was used for the ChIP assay following the manufacturer's protocol. In brief, glycine was used to quench ATC cells after they had been cross-linked for 10 min at 37 °C using 1% formaldehyde solution. Ultrasonication was used to cut the DNA into 200–1000 bp fragments. Then the chromatin solution was immunoprecipitated with anti-H3K4me3 or IgG antibodies (1:100). Eluted DNA was purified by DNA Purification Kit (Beyotime, China, D0033) according to the manufacturer's procedure and analyzed the enriched genomic DNA regions by qRT-PCR. The primer sequence is listed in Table 3.

Mg²⁺ measurement

Mag-Fura-4 AM (MKBio, China, MX4504-50UG) were added into cell culture media for 1 h at 37 °C following the manufacturer's instruction. After washed with PBS 3 times, cells were incubated with 1 mM probenecid for 30 min and detected by FCM.

Immunofluorescent staining and Giemsa staining

For immunofluorescent (IF) staining, cells were fixed with paraformaldehyde and blocked with 5% BSA. 0.2% Triton-X 100 was used for cell permeation. Then, cells were incubated with primary antibodies against NUF2 (1:200) and α -tubulin (1:200) at 4 °C overnight followed by secondary fluorescent antibodies protected from light for 2 h. And then, cells were washed with PBS for three times and incubated with DAPI for 15 min. Imaging was carried out using a fluorescence microscope.

Giemsa staining experiments were performed according to the instructions of the rapid Giemsa staining kit (BBI Life Sciences Corporation, China, E607314-0001). The cells were fixed with 4% paraformaldehyde for 10 min at RT and then incubated with the Giemsa staining working solution (solution I: solution II = 1:9) for 30 min at RT. After washed with PBS for 3 times, cells were observed and recorded under a microscope.

Animal models

Fertilized eggs from wild-type AB strains of zebrafish were cultivated in E3 embryo medium containing 0.2 mM 1-phenyl-2-thio-urea (PTU; Sigma, Germany) at 28 °C. WT or NUF2-KD ATC cells (8505C and KHM-5M) were labeled with 5 μ g/mL Dil for 15–30 min at 37 °C in the dark. Resuspended cells were injected into the perivitelline space of zebrafish at 48 h-post-fertilization (hpf). Zebrafishes were imaged under the fluorescence microscope at 0 and 3 days after microinjection, respectively. Re.Size = Fluorescence area at 3 days/Fluorescence area at 0 days.

Four-week-old female BALB/c nude mice were randomly assigned ($n = 6$ /group) to established mouse models. WT or NUF2-KD 8505 C cells (4×10^6) were collected and resuspended in 100 μ L PBS supplemented with 10% Matrigel (v/v) and then injected subcutaneously into nude mice. The body weight and tumor volume of the tumor-bearing mice were measured and recorded every 2–3 days. The tumor volumes were calculated as follows: Tumor volume = length \times width²/2. At the endpoint, the mice were sacrificed, and tumor tissues were excised, weighted and photographed.

To establish ATC orthotopic models, luciferase-labeled 8505 C cells were resuspended in PBS (1×10^7 /mL), and 10 μ L of the cell suspension was injected into the thyroid lobe of 6-week-old nude mice by neck surgery. Mice were anesthetized with isoflurane and injected with 100 μ L α -luciferin (3 mg/mouse) for bioluminescent imaging. As for the ATC pulmonary metastasis, luciferase-labeled 8505 C cells (1×10^6) was suspended in 100 μ L PBS and injected into the tail vein of nude mice. The bioluminescent imaging was performed weekly, for 4 weeks.

The animal protocols were approved by the Animal Welfare Committee of Zhejiang Provincial People's Hospital (Approved number: 20210510011).

Protein synthesis assay

The Global Protein Synthesis Assay Kit (Abcam, America, ab235634) was used to detect the protein synthesis efficiency. The cells were incubated with the protein label for 0.5–2 h at 37 °C. Cells were fixed by Fixation solution for 15 min at RT in the dark and then incubated with 1 × Reaction cocktail for 30 min at RT in the dark. After washing and proceeding with DNA staining, cells were analyzed by fluorescence microscope and FCM.

Data processing and statistical analysis

Statistical significance between the two groups was calculated by two-tailed Student's *t*-test. Two-sided $P < 0.05$ was considered statistically significant. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$). Graphical abstract was drawn by Figdraw.

RESULTS

NUF2 was overexpressed in ATC and correlated with poor prognosis

According to the survival analysis and expression level analysis based on nodal metastasis status, high expression of NUF2 was correlated with poor prognosis and positively related with nodal metastasis status (Fig. 1A, B). Besides, NUF2 was overexpressed in ATC according to the thyroid-cancer cohort reported previously [39] (Fig. 1C). Further IHC staining of tissue microarray confirmed that NUF2 expressed at a higher level in ATC tissues (H-score = 86.73) than normal thyroid tissues (H-score = 44.27) (Fig. 1D, E). The mRNA and protein expression levels of NUF2 were also upregulated in the ATC cell lines, KHM-5M and 8505 C, compared to the thyroid follicular epithelial cell line, Nthy-ori 3-1, and the PTC cell line, BCPAP (Fig. 1F–H). Collectively, these data support that NUF2 was upregulated in thyroid cancer and its level is positively correlated with poor prognosis. Subsequently, we explored the expression of NUF2 in different cell localizations and cell cycle phases. The result of nucleocytoplasmic separation showed that nuclear NUF2 was remarkably increased in ATC than that of Nthy-ori 3-1 (Fig. 1I–J). Although NUF2 was known as a component of kinetochore complex, it gradually increased along the cell cycle, and expressed most abundantly in G2/M phase (Fig. 1K), indicating a complicated role of NUF2 in ATC.

NUF2 is associated with proliferation and apoptosis in ATC cells

In order to understand the function of NUF2 in thyroid cancer, we then evaluated the effects of NUF2 on ATC cell proliferation and apoptosis in vitro. The transfected efficiency of siRNA-NUF2 (Fig. S1A, B) and NUF2 overexpression lentiviruses (Fig. S1C, D) was validated using qRT-PCR and western blot. The deletion of NUF2-induced karyokinesis and increased the separation error percentage. NUF2-KD ATC cells were accumulated in G2/M phase while NUF2 overexpression reduced the percentage BCPAP cells in G2/M phase (Fig. S2). NUF2 knockdown in ATC cells significantly attenuated proliferation potency (Fig. 2A). In contrast, overexpression of NUF2 notably increased cell viability (Fig. 2B). Colony formation ability was inhibited in NUF2-KD ATC cell lines and increased in NUF2-OE PTC cell lines (Fig. 2C, D). Cell division determined by CFSE confirmed that loss of NUF2 hindered ATC proliferation (Fig. 2E). Furthermore, knockdown of NUF2 dramatically induced apoptosis in ATC cell lines (Fig. 2F). Live/Dead assay was then used to evaluate the effect of NUF2 knockdown on ATC viability. The percentage of dead cells labeled with PI (red) was increased after knocking down NUF2 compared with that of control (Fig. 2G, H). These results suggested that NUF2 is essential for the growth and survival of thyroid cancer cells.

NUF2 promoted ATC tumor growth and metastasis in vivo

To investigate the effect of NUF2 on tumor growth in vivo, we implanted control or NUF2-knockdown ATC cells into zebrafish and nude mice. In zebrafish-CDX model, the fluorescence size of

ATC xenograft in NUF2-knockdown group was significantly decreased after 3 days (Fig. 3A, B). The fluorescence size of 8505 C and KHM-5M decreased by 2.6 times and 10.2 times compared with those of control, respectively (Fig. 3C). Consistently, growth of ATC xenografts derived from nude mice were remarkably inhibited in NUF2-knockdown group compared with control (Fig. 3D, E). Both tumor volume and tumor weight were dramatically attenuated after deletion of NUF2 (Fig. 3F, G). The IHC staining of mice tumor tissues confirmed that NUF2 knockdown decreased the expression of proliferative nuclear marker Ki67 (Fig. 3H) [40]. In addition, we established orthotopic ATC tumor model in nude mice and found the tumor growth was significantly inhibited by effect of NUF2 knockdown (Fig. 3I, J). After NUF2-KD and control 8505C cells were injected into the tail vein nude mice, we collected images and calculated luciferase activity to dynamically evaluate the lung metastases. The result showed that NUF2 knockdown remarkably decreased the metastatic ability of ATC cells (Fig. 3K, L). Collectively, these results showed that NUF2 promoted the progression and metastasis of ATC in vivo.

NUF2 was required for the magnesium ion transport in ATC

To explore the underlying mechanism of NUF2 in ATC progression, RNA-sequencing (RNA-seq) analysis was performed to compare relative changes of gene expression in siNUF2 and control cells. Then, we performed GO analysis on the differentially expressed genes and listed the top 20 enriched pathways in Fig. 4A. Notably, magnesium ion transport pathways ranked in the top 3 (Fig. 4A). The magnesium ion transport pathways consist of three typical magnesium ion transport-related genes (MAGT1, NIPA1, NIPAL1), and they were down-regulated in NUF2-knockdown ATC cells (Fig. 4B). Consistently, the results of qRT-PCR and western blot proved that NUF2 knockdown in ATC cell lines inhibited the mRNA and protein expression level of MAGT1, NIPA1 and NIPAL1 (Fig. 4C, D). Compared with Nthy-ori 3-1, the thyroid cancer cell lines especially ATC cell lines showed a higher level of intracellular magnesium ion concentration (Fig. 4E). The deletion of NUF2 decreased the intracellular magnesium ion concentration in ATC cell lines indicating a potential of NUF2 in regulating magnesium transportation (Fig. 4F). In conclusion, NUF2 was related with the magnesium ion transport process in ATC cells.

NUF2 promoted cell proliferation by regulating magnesium transporters

To uncover the role of magnesium transporters in ATC progression, we knock down MNN (MAGT1, NIPA1, and NIPAL1) in ATC cells and verified the knockdown efficiency (Fig. S1E, F). Loss of MAGT1, NIPA1, and NIPAL1 showed significantly decreased cell viability and colony formation ability in ATC cells (Fig. 5A, B). In addition, the deletion of magnesium transporters increased the percentage of apoptotic cells (Fig. 5C). Moreover, we further investigated whether MNN is a key mediator of the oncogenic effect of NUF2 in ATC. CCK-8 assay presented that knockdown of MNN abolished NUF2-induced promotion of tumor growth (Fig. 5D). The result of colony formation showed that depletion of MNN abolished NUF2-induced promotion of colony formation ability (Fig. 5E). In general, these results showed that the upregulation of magnesium transporters was partly responsible for NUF2-mediated tumor progression in ATC.

NUF2 regulates the transcription of magnesium ion transporters by H3K4me3

Next, we explored the mechanism underlying magnesium signaling regulated by NUF2. Subsequently, MAGT1, NIPA1 and NIPAL1 promoter-luciferase reporter plasmids were constructed and transfected into 293T cells individually. The result of dual-luciferase reporter (DLR) gene assays showed that NUF2 overexpression significantly elevated the transcriptional activity of MNN (Fig. 6A). Considering that histone modification is




Fig. 1 Expression of NUF2 in ATC and clinical relevance. **A** The relevance of NUF2 expression and relapse-free survival (RFS) in patients with thyroid cancer (TC). **B** Expression of NUF2 in TC subgroups based on nodal metastasis status. **C** The expression of NUF2 in NT, PTC, PDTC, and ATC based on four microarray datasets from GEO database. **D**, **E** IHC staining of NUF2 in NT and ATC tissues. **F–H** The mRNA and protein levels of NUF2 in different thyroid cancer cell lines. **I**, **J** The expression of NUF2 in cytoplasm and nucleus. **K** The expression of NUF2 in different cell cycle phases. Data are presented as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Fig. 2 Expression of NUF2 is associated with proliferation and apoptosis in ATC cells. **A** In vitro growth curves of ATC cells transfected with siNUF2. **B** In vitro growth curves of BCPAP cells after NUF2 overexpression. **C** Colony formation of ATC cells transfected with siNUF2. **D** Colony formation of BCPAP cells with NUF2 overexpression. **E** The cell division was determined by CFSE after NUF2 knockdown by siRNA. **F** Apoptosis of ATC cells 48 h after NUF2 knockdown by siRNA. **G**, **H** Cell viability of ATC cells transfected with siNUF2 (Live cells: Calcein-AM, Dead cells: PI). Data are presented as the mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.




Fig. 3 NUF2 promoted ATC tumor growth and metastasis in vivo. **A–C** Tumor growth from zebrafish-CDX model in control and NUF2-KD groups. **D** Weight growth curve of nude mice. **E, F** The ATC xenograft tumor volume and growth curve in nude mice. **G** Tumor weight of control and NUF2-KD groups. **H** IHC staining of Ki67 in mouse xenografts. **I** Representative images showing luciferase activity in orthotopic ATC tumor xenograft. **J** Luciferase activity curve of orthotopic ATC tumor model. **K, L** The tumor metastasis in nude mice. $n = 6$ mice per group. Data are presented as the mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Fig. 4 NUF2 knockdown inhibited the magnesium ion transport pathway in ATC. **A** Top 20 of GO enrichment according to the data of RNA-sequencing in 8505C cells which were transfected with siRNA-NUF2 and siRNA-NC, respectively. **B** The expression levels of genes in magnesium ion transport pathway. **C, D** The mRNA and protein levels of MAGT1, NIPA1, and NIPAL1 in NUF2-WT and NUF2-KD ATC cells. **E** The intracellular Mg^{2+} concentration of Nthy-ori 3-1, BCPAP, KHM-5M, and 8505C cell lines. **F** The intracellular Mg^{2+} concentration of NUF2-WT and NUF2-KD ATC cells (8505C, KHM-5M). Data are presented as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Fig. 5 NUF2 promoted cell proliferation by regulating magnesium transporters. **A** Cell viability of 8505C and KHM-5M cells transfected with siMNN (MAGT1 + NIPA1 + NIPAL1) or siRNA-NC. **B** Colony formation of control or siMNN 8505 C and KHM-5M cells. **C** Apoptosis of control and siMNN ATC cells. Growth curve (**D**) and colony formation (**E**) of BCPAP cells with NUF2 overexpression and siMNN. Data are presented as the mean \pm SD. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

essential for modulating the transcription of downstream genes, we sought to assess the possible histone modification at the promoter of MNN in thyroid glands. Based on the prediction of the SCREEN database (<https://screen.encodeproject.org/>), we found that the mean max-Z score of H3K4me3 was higher than H3K27ac at the promoter of MNN in four thyroid tissues, indicating that H3K4me3 might regulate the transcription of MNN (Fig. 6B). Immunofluorescence staining showed that H3K4me3 and NUF2 were highly expressed in 8505 C and they were expressed in the same site of nuclear (Fig. 6C). In addition, CoIP assay also demonstrated the interaction between H3K4me3 and NUF2 (Fig. 6D). According to the prediction of the SCREEN database, we designed and synthesized the corresponding primers (Table 3) for ChIP-qPCR. The result showed that NUF2 knockdown significantly inhibited H3K4me3 occupancy on the MNN promoter (Fig. 6E–G). Taken together, these findings demonstrated that NUF2 regulates the transcription of magnesium transporters by H3K4me3.

NUF2-mediated magnesium homeostasis affected the efficiency of protein synthesis

It has been demonstrated that intracellular Mg^{2+} plays a central role in the regulation of DNA and protein synthesis [7].

Therefore, we detected the nascent proteins in cells used a protein synthesis assay kit and the protein synthesis in NUF-KD ATC cells were significantly inhibited. Consistently, there were fewer nascent proteins in cells that simultaneously knocked down MAGT1, NIPA1, and NIPAL1 (Fig. 7A–C). It has been verified that the PI3K/Akt/mTOR pathway participated in the protein synthesis, and Mg^{2+} could regulate the activation of the PI3K/Akt/mTOR pathway [41]. Thus, we try to explore whether NUF2-mediated magnesium homeostasis affected the efficiency of protein synthesis by PI3K/Akt/mTOR pathway. The Spearman correlation analysis demonstrated the positive correlation between the expression level of NUF2 and mTOR signaling in ATC samples (Fig. 7D). Compared with NUF2-WT group, the expression level of p-mTOR was lower in NUF2-KD mouse xenograft tissues (Fig. 7E). Furthermore, we tested the IC50 of mTOR inhibitor RAPA (Fig. S3) and RAPA at the concentration of IC50 was added to BCPAP cells. The result showed that the increased protein synthesis induced by NUF2 overexpression could be partially weakened by mTOR inhibition (Fig. 7F, G). The knockdown of NUF2 or MNN inhibited the phosphorylation of PI3K/Akt/mTOR in ATC cells (Fig. 7H). Moreover, we demonstrated the rescue effects of MNN for the upregulation of PI3K/Akt/mTOR pathway induced by NUF2. The promoting effect of




Fig. 6 NUF2 regulate the transcription of magnesium ion transporters by H3K4me3. **A** Relative luciferase activity in 293T cells treated with pcDNA3.1 empty vector and NUF2 plasmids. **B** Max-Z score of H3K4me3 and H3K27ac in the thyroid glands of four patients. **C** Double immunofluorescence for NUF2 and H3K4me3 in 8505 C and Nthy-ori 3-1 cells. **D** Coimmunoprecipitation (CoIP) assay of NUF2, H3K4me3 and H3K27ac. **E-G** The abundance of H3K4me3 at the MAGT1, NIPA1 and NIPAL1 promoters in ATC cell lines was analyzed by chromatin immunoprecipitation. Data are presented as the mean \pm SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

NUF2 overexpression on PI3K/Akt/mTOR pathways could be in part reversed by MNN knockdown (Fig. 7I). These experiments indicated NUF2-mediated magnesium homeostasis affected PI3K/Akt/mTOR pathway, then influencing the efficiency of protein synthesis.

DISCUSSION

ATC is the most fatal subset of TC [1] and is characterized by a rapid growth rate which results in neck compression symptoms and death [3, 4]. NUF2 has been reported upregulated in various kinds of cancers including colorectal, gastric, breast, renal, and




Fig. 7 NUF2-mediated magnesium homeostasis affected the efficiency of protein synthesis by PI3K/Akt/mTOR pathway. **A–C** Nascent proteins in ATC cells transfected with siNUF2 or siMNN. **D** Spearman correlation analysis of mTOR signaling score and NUF2 expression in ATC samples. **E** IHC staining of p-mTOR in mouse xenografts. **F, G** Protein synthesis in WT and NUF2-OE BCPAP cells treated with mTOR inhibitor RAPA. **H** Western blot analysis of PI3K/Akt/mTOR signaling followed by NUF2 knockdown or siMNN. **I** Western blot analysis of PI3K/Akt/mTOR signaling followed by NUF2 overexpression and siMNN. Data are presented as the mean \pm SD. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$.

ovarian cancer [29, 30, 32, 42, 43]. Deletion of NUF2 can significantly inhibit the tumorigenesis and progression of cancers in vitro and in vivo [44–46]. However, there were little study on the function of NUF2 in ATC. In our study, we confirmed that NUF2 is a crucial regulator for protein synthesis in ATC. NUF2 transcriptionally regulates the expression of magnesium transporters by affecting H3K4me3 abundance at the promoter, thereby mediating magnesium homeostasis and promoting protein synthesis, which finally drives ATC progression.

NUF2 has been widely known as a constituent part of the NDC80 kinetochore complex and participated in maintaining the stability of kinetochore-microtubule attachments and chromosome alignment in mitosis. Consistent with its function, NUF2 was widely considered to play a pro-tumor role by regulating cell division and DNA replication [29, 34]. We found that NUF2 knockdown induced karyokinesis and increased the separation error percentage in ATC. High rates of separation error rates led to cell death and tumor suppression [47]. Recent research also revealed that NUF2 may drive cancer progression through other mechanisms. For example, NUF2 was identified as a new cancer stem cell indicator in breast cancer [30]. In ovarian cancer, NUF2 contributed to tumor initiation and development through PI3K-AKT and MAPK signaling axes mediated by ERBB3 [42, 43]. In addition, NUF2 can also facilitate the development of cholangiocarcinoma through p38/MAPK signaling by suppressing the p62 binding of TFR1 and affecting its autophagic degradation [31]. NUF2 acts as an oncogene in renal cancer by affecting the expression of HMGA2 by KDM2A-mediated H3K36me2 demethylation [32]. Our finding showed that NUF2 was required for the survival and tumor growth of ATC, which was dependent on NUF2-mediated magnesium ion homeostasis. 8505C cell line was from an ATC tissue while KHM-5M cell line was from a pleural metastasis. The differences in genetic background between the 8505C cell line and the KHM-5M cell line may contribute to their difference in cell proliferation and apoptosis. In our research, 8505C cell lines showed higher expression level of NUF2 than KHM-5M. Compared with 8505C cell line, knockdown of NUF2 inhibited the proliferation and induced cell apoptosis in vitro more dramatically in KHM-5M cell line. In the CDX model of zebrafish, knockdown of NUF2 resulted in more significant tumor suppression in KHM-5M cells than in 8505C cells.

Magnesium is an essential ion that plays an indispensable role in various kinds of cellular processes including cell proliferation, migration, and apoptosis [48]. Magnesium was normally regarded as 'second messenger' to regulate multiple reactions involving the response to growth factors that eventually lead to cell division [49]. The efficiency of protein and DNA synthesis increased sharply with small increases of intracellular Mg^{2+} in the physiological range [8]. Hypomagnesemia has been shown to prevent angiogenesis and tumor growth [15]. The intracellular magnesium concentration was regulated by some magnesium transporters including NIPA1, NIPAL1, and MAGT1 [10–13]. These magnesium transporter genes also be related with cancer progression. For example, NIPA1 [18, 19] and NIPAL1 [20, 21] were related with poor prognosis of cancers, and MAGT1 knockdown inhibited tumor progression [16, 17]. The result of our study has demonstrated that NUF2 is involved in the magnesium ion transport in ATC. Furthermore, we found that NUF2 regulated the transcription of magnesium transporters by increasing the abundance of H3K4me3 at the promoter, which is regarded as one of the most recognized epigenetic marks of active transcription [50].

The dysregulation of protein synthesis is a distinctive feature of the cancer cells. The rapid proliferation of cancers requires the synthesis of large amounts of proteins in cells [6]. The active protein synthesis was supported by increased eukaryotic initiation factor and ribosome biogenesis [23–26], thereby promoting the aggressiveness and chemoresistance of ATC. However, the exact

mechanism underlying protein synthesis in ATC still remains unknown. The PI3K/Akt/mTOR signaling is essential for the regulation of many basic cellular processes including protein synthesis and the dysregulation of PI3K/Akt/mTOR signaling is associated with cancer progression [41]. It has been reported that magnesium influx mediated by TRPM7-regulated signaling throughout the PI3K/Akt/mTOR pathway [51, 52]. Besides, studies have shown that mTOR may be a magnesium-sensitive crucial regulator of protein synthesis related with proliferative signaling [49]. This evidence supports the hypothesis that magnesium ions influence protein synthesis by PI3K/AKT/mTOR pathway. Therefore, we try to establish a link between NUF2-mediated magnesium homeostasis and protein synthesis. It has been shown in our study that the knockdown of NUF2 or magnesium transporters significantly inhibited PI3K/Akt/mTOR signaling and protein synthesis efficiency.

In conclusion, our study showed that NUF2 epigenetically promotes the transcription of magnesium transporters and facilitates Mg^{2+} -dependent protein synthesis by activating PI3K/Akt/mTOR pathway, thereby driving the malignant phenotype of ATC.

DATA AVAILABILITY

The data supporting the conclusions of this paper have been provided in this paper and GEO database. In addition, all data for this study are available from the corresponding author upon reasonable request.

REFERENCES

- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017;67:7–30.
- Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. *Mol Cancer*. 2018;17:154.
- Agosto Salgado S. Evolution of anaplastic thyroid cancer management: perspectives in the era of precision oncology. *Ther Adv Endocrinol Metab*. 2021;12:20420188211054692.
- Jannin A, Escande A, Al Ghuzlan A, Blanchard P, Hartl D, Chevalier B, et al. Anaplastic thyroid carcinoma: an update. *Cancers*. 2022;14:1061.
- Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting. *EMBO J*. 2022;41:e109823.
- Shamir M, Bar-On Y, Phillips R, Milo R. SnapShot: timescales in cell biology. *Cell*. 2016;164:1302–1302.e1301.
- Cameron IL, Smith NK. Cellular concentration of magnesium and other ions in relation to protein synthesis, cell proliferation and cancer. *Magnesium*. 1989;8:31–44.
- Rubin H. Intracellular free $Mg(2+)$ and $MgATP(2-)$ in coordinate control of protein synthesis and cell proliferation. In: Vink R, Nechifor M, editors. *Magnesium in the central nervous system*. Adelaide (AU): University of Adelaide Press © 2011 The Authors; 2011
- Terasaki M, Rubin H. Evidence that intracellular magnesium is present in cells at a regulatory concentration for protein synthesis. *Proc Natl Acad Sci USA*. 1985;82:7324–6.
- Goytain A, Hines RM, El-Husseini A, Quamme GA. NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional $Mg2+$ transporter. *J Biol Chem*. 2007;282:8060–8.
- Manialawy Y, Khan SR, Bhattacharjee A, Wheeler MB. The magnesium transporter NIPAL1 is a pancreatic islet-expressed protein that conditionally impacts insulin secretion. *J Biol Chem*. 2020;295:9879–92.
- Meossi C, Carrer A, Ciaccio C, Estienne M, Silipigni R, Sciacca FL, et al. Clinical features and magnesium levels: Novel insights in 15q11.2 BP1-BP2 copy number variants. *J Intellect Disabil Res*. 2023;67:679–89.
- Wolf FI, Trapani V. MagT1: a highly specific magnesium channel with important roles beyond cellular magnesium homeostasis. *Magn Res*. 2011;24:586–91.
- Wolf FI, Trapani V. Magnesium and its transporters in cancer: a novel paradigm in tumour development. *Clin Sci*. 2012;123:417–27.
- Maier JA, Nasulewicz-Goldeman A, Simonacci M, Boninsegna A, Mazur A, Wolf FI. Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. *Nutr Cancer*. 2007;59:192–8.
- Cazzaniga A, Moscheni C, Trapani V, Wolf FI, Farruggia G, Sargenti A, et al. The different expression of TRPM7 and MagT1 impacts on the proliferation of colon carcinoma cells sensitive or resistant to doxorubicin. *Sci Rep*. 2017;7:40538.

17. Li L, Zhang X, Li Y, Xiao B, Pei S, Jiang H, et al. Transcription factor KLF16 activates MAGT1 to regulate the tumorigenesis and progression of breast cancer. *Int J Mol Med*. 2022;50:115.
18. Liu H, Zhao H. Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma. *Neoplasma*. 2019;66:487–93.
19. Wan Q, Tang J, Lu J, Jin L, Su Y, Wang S, et al. Six-gene-based prognostic model predicts overall survival in patients with uveal melanoma. *Cancer Biomark*. 2020;27:343–56.
20. Sasahira T, Nishiguchi Y, Kurihara-Shimomura M, Nakashima C, Kuniyasu H, Kirita T. NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma. *J Cancer Res Clin Oncol*. 2018;144:875–82.
21. Yu G, Hsu WL, Coghill AE, Yu KJ, Wang CP, Lou PJ, et al. Whole-exome sequencing of nasopharyngeal carcinoma families reveals novel variants potentially involved in nasopharyngeal carcinoma. *Sci Rep*. 2019;9:9916.
22. Lu C, Makala L, Wu D, Cai Y. Targeting translation: eIF4E as an emerging anti-cancer drug target. *Expert Rev Mol Med*. 2016;18:e2.
23. Pelletier J, Thomas G, Volarević S. Ribosome biogenesis in cancer: new players and therapeutic avenues. *Nat Rev Cancer*. 2018;18:51–63.
24. Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A, van Staveren WC, et al. Thyroid cancer cell lines: an overview. *Front Endocrinol*. 2012;3:133.
25. Hu K, Zhang J, Yu M, Xiong C. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer. *Future Oncol*. 2017;13:489–98.
26. Hsu SH, Hung WC. Protein arginine methyltransferase 3: A crucial regulator in metabolic reprogramming and gene expression in cancers. *Cancer Lett*. 2023;554:216008.
27. Wigge PA, Kilmartin JV. The Ndc80p complex from *Saccharomyces cerevisiae* contains conserved centromere components and has a function in chromosome segregation. *J Cell Biol*. 2001;152:349–60.
28. DeLuca JG, Howell BJ, Canman JC, Hickey JM, Fang G, Salmon ED. Nuf2 and Hec1 are required for retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. *Curr Biol*. 2003;13:2103–9.
29. Jiang X, Jiang Y, Luo S, Sekar K, Koh CKT, Deivasigamani A, et al. Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers. *Cancer Res Treat*. 2021;53:944–61.
30. Deng Y, Li J, Zhang Y, Hu H, Wan F, Min H, et al. NUF2 promotes breast cancer development as a new tumor stem cell indicator. *Int J Mol Sci*. 2023;24:4226.
31. Shan J, Jiang W, Chang J, Zhou T, Chen Y, Zhang Y, et al. NUF2 drives cholangiocarcinoma progression and migration via inhibiting autophagic degradation of TFR1. *Int J Biol Sci*. 2023;19:1336–51.
32. Lin J, Chen X, Yu H, Min S, Chen Y, Li Z, et al. NUF2 drives clear cell renal cell carcinoma by activating HMG2A transcription through KDM2A-mediated H3K36me2 demethylation. *Int J Biol Sci*. 2022;18:3621–35.
33. DeLuca JG, Moree B, Hickey JM, Kilmartin JV, Salmon ED. hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. *J Cell Biol*. 2002;159:549–55.
34. Wang D, Chen J, Li B, Jiang Q, Liu L, Xia Z, et al. A noncoding regulatory RNA Gm31932 induces cell cycle arrest and differentiation in melanoma via the miR-344d-3-5p/Prc1 (and Nuf2) axis. *Cell Death Dis*. 2022;13:314.
35. Dom G, Tarabichi M, Unger K, Thomas G, Oczko-Wojciechowska M, Bogdanova T, et al. A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. *Br J Cancer*. 2012;107:994–1000.
36. von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, et al. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. *J Clin Endocrinol Metab*. 2015;100:E697–709.
37. Wen S, Qu N, Ma B, Wang X, Luo Y, Xu W, et al. Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer. *Onco Targets Ther*. 2021;14:1205–17.
38. Pan Z, Xu T, Bao L, Hu X, Jin T, Chen J, et al. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor micro-environment. *Mol Cancer*. 2022;21:190.
39. Pan Z, Bao L, Lu X, Hu X, Li L, Chen J, et al. IL2RA(+)VSI4(+) tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer. *Biochim Biophys Acta Mol Basis Dis*. 2023;1869:166591.
40. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. *Clin Chim Acta*. 2019;491:39–45.
41. Popova NV, Jücker M. The role of mTOR signaling as a therapeutic target in cancer. *Int J Mol Sci*. 2021;22:1743.
42. Leng R, Meng Y, Sun X, Zhao Y. NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes. *Front Oncol*. 2022;12:1057198.
43. Ren M, Zhao H, Gao Y, Chen Q, Zhao X, Yue W. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer. *J Ovarian Res*. 2023;16:17.
44. Fu HL, Shao L. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. *Eur Rev Med Pharmacol Sci*. 2016;20:1071–9.
45. Hu P, Chen X, Sun J, Bie P, Zhang LD. siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. *Biosci Rep*. 2015;35:e00170.
46. Liu Q, Dai SJ, Li H, Dong L, Peng YP. Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. *Asian Pac J Cancer Prev*. 2014;15:8623–9.
47. Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, et al. Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. *Sci Transl Med*. 2021;13:eabd4811.
48. Wolf FI, Trapani V. Cell (patho)physiology of magnesium. *Clin Sci*. 2008;114:27–35.
49. Rubin H. The logic of the Membrane, Magnesium, Mitosis (MMM) model for the regulation of animal cell proliferation. *Arch Biochem Biophys*. 2007;458:16–23.
50. Park S, Kim GW, Kwon SH, Lee JS. Broad domains of histone H3 lysine 4 trimethylation in transcriptional regulation and disease. *FEBS J*. 2020;287:2891–902.
51. Sahni J, Scharenberg AM. TRPM7 ion channels are required for sustained phosphoinositide 3-kinase signaling in lymphocytes. *Cell Metab*. 2008;8:84–93.
52. Sahni J, Tamura R, Sweet IR, Scharenberg AM. TRPM7 regulates quiescent/proliferative metabolic transitions in lymphocytes. *Cell Cycle*. 2010;9:3565–74.

AUTHOR CONTRIBUTIONS

Minghua Ge, Ping Huang and Zongfu Pan conceived and designed the experiments; Lisha Bao, Yingying Gong, Yulu Che and Ying Li performed the experiments and analyzed the data; Tong Xu, Jinming Chen and Shanshan Wang prepared the tables and figures. Zhuo Tan contributed to obtaining the patient tissue samples; Lisha Bao and Zongfu Pan supervised the study and wrote the manuscript. All authors contributed to the research and approved the submitted version.

FUNDING

Research was supported by the National Natural Science Foundation of China under Grant (Nos. U20A20382, 82273287, 82173157, 82161138019), Central Government Guides Local Science and Technology Development Project (No. 2023ZY1059), Natural Science Foundation of Zhejiang Provincial under Grant (Nos. LY22H160041 and LY22H160036), Medical and Health Science and Technology Project of Zhejiang Province (No. 2022KY042), and Chinese Medicine Research Program of Zhejiang Province (No. 2022ZZ001), Zhejiang Provincial Program for the Cultivation of High-level Health Talents (to Zongfu Pan), Zhejiang Provincial Science and Technology Program (No. 2022R51002), Key Research and Development Program of Zhejiang Province under Grant No. 2024C03157.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Zhejiang Provincial People's Hospital. All subjects provided informed consent prior to using the tissues samples for scientific research.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-024-07041-6>.

Correspondence and requests for materials should be addressed to Ping Huang, Zongfu Pan or Minghua Ge.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024, corrected publication 2024